New insights into the burden and costs of multiple sclerosis in Europe: Results for Germany.

Introduction To estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated.Objectives and methods This study is part of a cross-sectional retros... View More